- Date: November 14, 2017
Back in 1991, 14 November was the date set by the International Diabetes Federation and the World Health Organisation for World Diabetes Day. The event is the largest campaign of its kind to raise awareness of the metabolic disease, and reaches over 1 billion people worldwide.
One of the objectives of CaixaImpulse is to promote research transfer to the market in order to improve people’s health. Diabetes is a several complex condition affecting the quality of life of many people worldwide. In general, diabetes patients are to some extent unable to control the amount of sugar levels in their blood, and this is the focus of most treatments. However, this treatment results in some patients developing fatty liver disease.
Finding a new treatment for diabetic patients with associated fatty liver disease is one of the objectives of the APODRUG project. The project took part in CaixaImpulse in 2016, and is led by scientists from the Center for Applied Medical Research (CIMA) at the University of Navarra.
November 17, 2017
On 10 November, participants pitched their valorisation plans to the CaixaImpulse Valorisation Panel, who will confirm the grants offered to each project. The upcoming months will be devoted to execute the actions included in their respective plans.
November 10, 2017
GlyCardial Diagnostics, which was founded last September, has raised an investment of €2.4 million from Caixa Capital Risc, with participation from the Healthequity SCR fund.
November 08, 2017
Werium Assistive Solutions is a spin-off that participated in the first ever CaixaImpulse programme. In this short interview, we talk with its CEO, Rafael Raya, to find out latest on the project.